

Bioasis Technologies Inc. is a multi-asset clinical stage rare and orphan disease company with three phase 2 ready programs based on epidermal growth factors for the treatment of Guillain-Barre Syndrome, Optic Neuritis in MS and CIDP. The company is concurrently advancing the extensive capabilities of the xB³™ platform for blood-brain barrier therapeutics delivery validated by global life sciences companies, including Chiesi, Johnson & Johnson, Neuramedy and Prothena.

Epidermal Growth Factor (“EGF”)

- Protein that stimulates cell growth and differentiation
- Stimulates oligodendrocyte and Schwann cell differentiation and maturation for remyelination




Neurodegenerative Disorders

- EGF levels are deficient in neurodegenerative disorders



EGF Treatment

- Stimulate myelin regeneration
- Protect nerve cells



Pipeline

Asset	Indication	Drug Discovery	Pre Clinical	Ph-1	Ph-2	Ph-3
Epidermal Growth Factor Platform						
CRES101	Guillain-Barre Syndrome (GBS)	→				
CRES101	Optic Neuritis associated with MS	→				
CRES101	Chronic Inflammatory Demyelinating Polyneuritis (CIDP)	→				
CRES202	Alzheimer's Disease	→				
xB³™ Platform						
xB ³ -008	Hunter Syndrome	→				
xB ³ -007	Gaucher Disease, PD, Lewy Body Dementia	→				
xB ³ -004	Multiple Sclerosis, Epilepsy, Autoinflammatory Diseases	→				
xB ³ -009	CLN, Frontotemporal Dementia ALS	→				

xB³ Platform

The Bioasis xB³™ patented platform provides researchers with a solution to one of medicine’s most stubborn challenges: how to transport medicines across the blood-brain barrier at doses sufficient to have a therapeutic effect. Scientists at Bioasis have worked for over a decade to develop our proprietary xB³ platform. Formerly called the Transcend-peptide, xB³ is based on a human transport protein found circulating at low levels in the blood. The xB³™ platform has shown high efficacy in its ability to shuttle molecules across the blood-brain barrier and reach its targets within the brain through a process called receptor-mediated transcytosis.

Corporate Structure

Capitalization (as of August 31, 2022)	Common Stock Equivalents
Common Stock ⁽¹⁾	79,414,015
Convertible Notes (convertible @ CAD\$0.31 / share)	9,193,548
Warrants (WAEP CAD\$0.43) ⁽²⁾	22,275,506
Options (WAEP CAD\$0.33)	9,434,690
Total Fully Diluted	120,317,759

(1) Includes 6.5 million shares issued to owners of Cresence AS in June 2022 as part of the asset purchase agreement
 (2) 4,839,048 warrants with an exercise price of CAD\$0.41 reset for down round offerings if shares are issued at a price < 95% of the market price

Strategic Partners



Contact Us

Deborah Rathjen, Ph.D., Executive Chair & CEO
deborah@bioasis.us; +1 203 533 7082
 Graeme Dick, Colwell Capital Corp.
graeme@colwellcapital.com; +1 403 561 8989